Next-generation sequencing market seen reaching $42.61B by 2035

Market Research Future projects the global next-generation sequencing market will grow from $11.02 billion in 2025 to $42.61 billion by 2035, driven by reimbursement for genomic testing, cheaper sequencing and expanding multiomics workflows. The report says the fastest growth is coming from clinical adoption, public genomics programs and broader use in cancer, rare disease and screening.

Why it matters: - The next-generation sequencing market is moving from research spending into routine clinical care. - Faster turnaround times and falling cost per genome are making genomic testing easier to scale across hospitals, labs and public health programs. - The market’s growth is tied to cancer diagnostics, rare disease workups, newborn screening and national genomics initiatives.

What happened: - Market Research Future projects the global next-generation sequencing market will rise from USD 11.02 billion in 2025 to USD 42.61 billion by 2035. - The report forecasts a 14.7% compound annual growth rate from 2026 to 2035. - The market is expected to reach USD 12.40 billion in 2026, the first year of the forecast period. - The forecast centers on three growth drivers: broader reimbursement, instrument improvements and multiomics adoption.

The details: - Clinical reimbursement for genomic profiling and large public sequencing programs are pushing comprehensive genomic profiling into routine care. - High-output sequencing systems and on-cartridge workflows are cutting turnaround times from days to hours. - Cost per genome has fallen below USD 200 on flagship platforms. - Single-cell and spatial transcriptomics are increasing reagent use on installed sequencers without requiring new capital purchases. - Illumina holds an estimated 34% to 40% revenue share. - Thermo Fisher Scientific is seeing sequencing-linked revenue growth from pharma service contracts. - NHGRI data shows per-genome pricing has dropped sharply since 2008. - The European Union’s 1+ Million Genomes initiative and India’s GenomeIndia programme are supporting public sequencing capacity. - A free sample request is available here. - A customisation request is available here. - The full report is available here.

Between the lines: - Reimbursement is turning sequencing into a billable clinical service, which lowers adoption risk for hospitals and diagnostic labs. - Public genomics programs create demand that is less dependent on research funding cycles. - The report suggests vendors with recurring consumables revenue and informatics tools have a structural advantage. - Multiomics growth may increase utilization of existing installed platforms, boosting application-layer revenue without the same pace of instrument purchases.

What's next: - The report expects demand to expand in emerging markets through bundled installation, informatics and workforce support. - Open-chemistry systems could pressure proprietary consumable models. - Machine learning-based variant interpretation may become more important as labs face workforce constraints. - Sustainability reporting is likely to become part of procurement scoring. - By segment, targeted resequencing remains the largest type at 35.4% in 2025, while whole exome sequencing is the fastest-growing at 15.2% CAGR. - Reagents and consumables lead product revenue with a 65.0% share in 2025, while instruments are the fastest-growing product category at 15.4% CAGR. - Drug discovery and personalized medicine is the largest application at USD 3.61 billion in 2025, while genetic screening is the fastest-growing application at 15.3% CAGR. - Academic institutes hold the largest end-user share at 45.1% in 2025, while hospitals and healthcare institutions are the fastest-growing end user at 15.6% CAGR. - North America leads regional revenue with 38.9% in 2025, or about USD 4.29 billion. - Europe is the second-largest region at USD 3.02 billion in 2025. - Asia-Pacific is projected to grow the fastest at 15.2% CAGR from 2026 to 2035. - South America was valued at USD 0.51 billion in 2025. - The Middle East and Africa hold about 3.3% of global share.

The bottom line: - Sequencing growth is shifting from a platform race to a reimbursement-and-scale story, with clinical demand, public investment and lower costs driving the next decade.